New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...
For people living with multiple sclerosis (MS), the search for effective treatment options can feel like a never-ending journey. While disease-modifying therapies (DMTs) have improved outcomes for ...
Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived ...
Key updates in disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) forum are reported ...
Editor's Note: The stem cell study mentioned below was retracted by The BMJ, according to a notice on March 31, 2026. TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, ...
Alemtuzumab is a humanised monoclonal antibody directed against the CD52 antigen on mature lymphocytes. In relapsing-remitting multiple sclerosis (RRMS), it is delivered as two annual intravenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results